Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis
Objective To evaluate association between biomarkers and outcomes in COVID-19
hospitalised patients. COVID-19 pandemic has been a challenge. Biomarkers have always …
hospitalised patients. COVID-19 pandemic has been a challenge. Biomarkers have always …
[HTML][HTML] ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
M Dong, J Zhang, X Ma, J Tan, L Chen, S Liu… - Biomedicine & …, 2020 - Elsevier
At the end of 2019, the coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Currently, it is …
respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Currently, it is …
Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
KI Zheng, F Gao, XB Wang, QF Sun… - Metabolism-clinical …, 2020 - metabolismjournal.com
Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020 [1].
Preliminary data suggests that obesity may aggravate the severity of respiratory diseases …
Preliminary data suggests that obesity may aggravate the severity of respiratory diseases …
Plasma CRP level is positively associated with the severity of COVID-19
W Chen, KI Zheng, S Liu, Z Yan, C Xu… - Annals of clinical …, 2020 - Springer
Aims The coronavirus disease 2019 (COVID-19) is characterized as highly contagious and
deadly; however there is no credible and convenient biomarker to predict the severity of the …
deadly; however there is no credible and convenient biomarker to predict the severity of the …
Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidity
J Huang, A Cheng, R Kumar, Y Fang… - Journal of medical …, 2020 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) has evolved into a pandemic rapidly.
Most of the literature show that the elevated liver enzymes in COVID‐19 are of little clinical …
Most of the literature show that the elevated liver enzymes in COVID‐19 are of little clinical …
Liver injury in COVID-19: The current evidence
SA Alqahtani, JM Schattenberg - United European …, 2020 - journals.sagepub.com
Patients with novel coronavirus disease 2019 (COVID-19) experience various degrees of
liver function abnormalities. Liver injury requires extensive work-up and continuous …
liver function abnormalities. Liver injury requires extensive work-up and continuous …
[HTML][HTML] Coronavirus disease (COVID-19): comprehensive review of clinical presentation
OP Mehta, P Bhandari, A Raut, SEO Kacimi… - Frontiers in Public …, 2021 - frontiersin.org
COVID-19 is a rapidly growing pandemic with its first case identified during December 2019
in Wuhan, Hubei Province, China. Due to the rampant rise in the number of cases in China …
in Wuhan, Hubei Province, China. Due to the rampant rise in the number of cases in China …
Abnormal liver tests in COVID‐19: a retrospective observational cohort study of 1,827 patients in a major US hospital network
MA Hundt, Y Deng, MM Ciarleglio, MH Nathanson… - …, 2020 - Wiley Online Library
Background and Aims The coronavirus‐19 disease (COVID‐19) pandemic, caused by the
severe acute respiratory syndrome coronavirus 2 virus, is associated with significant …
severe acute respiratory syndrome coronavirus 2 virus, is associated with significant …
[HTML][HTML] COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics
SA Azer - New Microbes and New Infections, 2020 - Elsevier
Abstract The novel coronavirus (COVID-19) outbreak started early in December 2019 in the
Hubei province and its capital Wuhan of the People's Republic of China and caused a …
Hubei province and its capital Wuhan of the People's Republic of China and caused a …
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
SK Sarin, A Choudhury, GK Lau, MH Zheng, D Ji… - Hepatology …, 2020 - Springer
Background and aims COVID-19 is a dominant pulmonary disease, with multisystem
involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic …
involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic …